(Q35065032)

6 August 2017

1 reference

title

Molecular pathogenesis and prognostic factors in endometrial carcinoma (English)

1 reference

6 August 2017

2

Lars A Akslen

1 reference

6 August 2017

1

Helga B Salvesen

1 reference

6 August 2017

1 October 2002

1 reference

Acta Pathologica et Microbiologica Scandinavica

6 August 2017

1 reference

6 August 2017

110

1 reference

6 August 2017

10

1 reference

6 August 2017

673-689

1 reference

Estrogen-progestin replacement therapy and endometrial cancer

6 August 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Reproductive factors and risk of endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Lymph node sampling and survival in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Adjuvant progestagen therapy for the treatment of endometrial cancer: review and meta-analyses of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Cell-cycle control and its watchman.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Familial endometrial cancer in female carriers of MSH6 germline mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

The p53 tumor suppressor gene frequently is altered in gynecologic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

P16/MTS1 and pRB expression in endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Alteration of p16 and p15 genes in human uterine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Cancer epigenetics comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Deletion mapping on chromosome 10q25-q26 in human endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

WAF1, a potential mediator of p53 tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Flow cytometric DNA analysis of stage I endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Progesterone receptor levels independently predict survival in endometrial adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Identification of patients with stage I uterine endometrioid adenocarcinoma at high risk of recurrence by DNA ploidy, myometrial invasion, and vascular invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Poorer survival of nulliparous women with endometrial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Independent prognostic importance of microvessel density in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Angiogenesis of the endometrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Uterine papillary serous carcinoma evolves via a p53-driven pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Tumour vasculature--a potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Antiangiogenic activity of the cleaved conformation of the serpin antithrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Cancer risk associated with germline DNA mismatch repair gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Life (and death) in a malignant tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

International Federation of Gynecology and Obstetrics staging of endometrial cancer 1988.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

21 January 2018

Endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Routine lymph node dissection in the treatment of early stage cancer: are we doing the right thing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Adenocarcinoma of the Endometrium: Survival Comparisons of Patients with and without Pelvic Node Sampling

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with stage I endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

An analysis of approaches to the treatment of endometrial cancer in Western Europe: A CTF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

An evaluation of routine follow-up of patients treated for endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Is there any value in the long term follow up of women treated for endometrial cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Detection and patterns of treatment failure in 300 consecutive cases of "early" endometrial cancer after primary surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Recurrence of endometrial carcinoma and the value of routine follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Mutations and amplification of oncogenes in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Mutant p53 protein as a predictor of survival in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

p16INK4andp15INK4BAlterations in Primary Gynecologic Malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid-type endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Effects of transforming growth factors and regulation of their mRNA levels in two human endometrial adenocarcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Model for the molecular genetic diagnosis of endometrial cancer using K-ras mutation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Nuclear morphometry and DNA flow cytometry as prognostic methods for endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Prognostic significance of hormone receptors in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

p53 as a prognostic indicator in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

HER-2/neu expression: a major prognostic factor in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Endometrial carcinomas--flow cytometric DNA content and S-phase values

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Prognostic significance of DNA ploidy in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Flow cytometric measurements of DNA index and S-phase on paraffin-embedded early stage endometrial cancer: an important prognostic indicator

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

DNA ploidy in endometrial carcinoma: major objective prognostic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

DNA ploidy status: its impact on early-stage endometrial adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Deoxyribonucleic acid analysis facilitates the pretreatment identification of high-risk endometrial cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Evaluation of DNA ploidy in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Prognostic value of flow cytometric deoxyribonucleic acid index in endometrial carcinoma: comparison with other clinical-pathologic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Prognostic value of DNA ploidy and S-phase fraction in endometrial cancer stage I and II: a prospective 5-year survival study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

The effect of nulliparity on survival in endometrial cancer at different ages

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Proliferation index determined by MIB-1 and recurrence in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

Angiogenesis in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Case-control study of endogenous steroid hormones and endometrial cancer

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Height and weight in relation to uterine corpus cancer morbidity and mortality. A follow-up study of 570,000 women in Norway

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Is the risk of cancer of the corpus uteri reduced by a recent pregnancy? A prospective study of 765,756 Norwegian women

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Endometrial cancer in a cohort screened for breast cancer

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Evaluation of different surgical approaches in the treatment of endometrial cancer at FIGO stage I

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Impact of improved irradiation technique, age, and lymph node sampling on the severe complication rate of surgically staged endometrial cancer patients: a multivariate analysis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

A randomized trial of adjuvant progestagen in early endometrial cancer

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Isolated vaginal recurrences of endometrial adenocarcinoma and their management

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Molecular basis of endometrial cancer

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

A cell cycle regulator potentially involved in genesis of many tumor types

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Tumor-suppressor p53: implications for tumor development and prognosis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Analysis of oncogene alterations in human endometrial carcinoma: prevalence of ras mutations

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

ras gene mutations in human endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

p53 gene mutations in human endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Mutation and allelic loss of the p53 gene in endometrial carcinoma. Incidence and outcome in 92 surgical patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Immunohistochemical localization of p21(WAF1/CIP1) in normal, hyperplastic, and neoplastic uterine tissues

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Low frequency of CDKN2 mutation in endometrial carcinomas

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

PTEN1 is frequently mutated in primary endometrial carcinomas

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Mutations predisposing to hereditary nonpolyposis colorectal cancer: Database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Mutation and cancer: statistical study of retinoblastoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Hereditary cancer: two hits revisited

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

DCC gene alteration in human endometrial carcinomas

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Localization of progesterone receptor with monoclonal antibodies to the human progestin receptor

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Molecular mechanisms of proliferation in endometrial tumour cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Microsatellite instability in cancer of the proximal colon

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Microsatellite instability in sporadic endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

p53 immunohistochemistry: a word of caution

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Endometrial adenocarcinoma in Norway. A study of a total population

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Serous papillary carcinoma of the endometrium: a histopathological study of 22 cases

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

The histologic grading of cancer

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Architectural (FIGO) grading, nuclear grading, and other prognostic indicators in stage I endometrial adenocarcinoma with identification of high-risk and low-risk groups

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Prognostic value of quantitative pathologic features and DNA content in individual patients with stage I endometrial adenocarcinoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

DNA ploidy and steroid receptors as predictors of disease course in patients with endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Flow cytometric studies of ploidy and proliferative indices in the Yorkshire trial of adjuvant progestogen treatment of endometrial cancer

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

The prognostic significance of DNA measurements in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Prognostic significance of ploidy level in human tumors. I. Carcinoma of the uterus

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Endometrial adenocarcinoma. A multiparameter clinicopathologic analysis including the DNA profile and the sex steroid hormone receptors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Relative prognostic significance of DNA flow cytometry and histologic grading in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Prognostic significance of proliferation in endometrial adenocarcinomas: a multivariate analysis of clinical and flow cytometric variables

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Five year survival rate in endometrial carcinoma stages I--II: influence of degree of tumour differentiation, age, myometrial invasion and DNA content

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Methodological aspects of flow cytometry DNA analysis in endometrial carcinoma, with special reference to sampling and reproducibility

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

DNA Content Is an Independent Prognostic Indicator in Endometrial Adenocarcinoma A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Proliferation markers in tumours: interpretation and clinical value

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Angiogenesis factor in endometrial carcinoma: a new prognostic indicator?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Clinicopathological characteristics of p53 overexpression in endometrial cancers

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma: a clinicopathologic and molecular comparison

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2002.1101001.X

7 January 2021

10.1034/J.1600-0463.2002.1101001.X

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12583434